WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Ethnic minority students participated in a fun campus game to welcome the Asian GamesA drink heritage to cherishTimes gone in a snapCulture Insider: China's Ghost FestivalWorld's largest span arch bridge opens to trafficChina Focus: Xi Urges Enhanced ChinaReturn looted relics to countries of originWriting New Stories of ChinaXi Sends Congratulatory Letter to 2023 Imperial Springs Int'l ForumInternational experts expect the Chinese economy to flourish with more technological breakthroughs